Abstract
Multi-drug resistant Neisseria gonorrhoeae infection is a significant public health risk. Rapidly detecting N. gonorrhoeae and antimicrobial resistant (AMR) determinants by metagenomic sequencing of urine is possible, although high levels of host DNA and overgrowth of contaminating species hamper sequencing and limit N. gonorrhoeae genome coverage. We performed Nanopore sequencing of nucleic acid amplification test-positive urine samples and culture-positive urethral swabs with and without probe-based target enrichment, using a custom SureSelect panel to investigate selectively enriching for N. gonorrhoeae DNA. Probes were designed to cover the entire N. gonorrhoeae genome, with 10-fold enrichment of probes covering selected AMR determinants. Multiplexing was tested in subset of samples. The proportion of sequence bases classified as N. gonorrhoeae increased in all samples after enrichment, from a median (IQR) of 0.05% (0.01-0.1%) to 76% (42-82%), giving a corresponding median improvement in fold genome coverage of 365-times (112–720). Over 20-fold coverage, required for robust AMR determinant detection, was achieved in 13/15 (87%) samples, compared to 2/15 (13%) without enrichment. The four samples multiplexed together also achieved >20x genome coverage. Coverage of AMR determinants was sufficient to predict resistance where present, and genome coverage also enabled phylogenetic relationships to be reconstructed. Probe-based target enrichment can improve N. gonorrhoeae genome coverage when sequencing DNA extracts directly from urine or urethral swabs, allowing for robust detection of AMR determinants. Additionally, multiplexing prior to enrichment provided enough genome coverage for AMR detection and reduces the costs associated with this method.
Impact statement Neisseria gonorrhoeae infection presents a significant public health risk, with multi-drug resistance present globally. Early detection helps control the spread of antimicrobial resistant strains. Genome sequencing can be used to detect infections in samples collected directly from patients, without the need to grow any microorganisms in a laboratory first, and this has already been demonstrated for gonorrhoea using urine samples. With enough sequence information it is also possible to detect antimicrobial resistance (AMR), allowing both detection of infection and information on treatment choices from the same test. This study assesses a method for enriching N. gonorrhoeae sequence data from urine and urethral swabs, and analyses the impact of enrichment on the detection of genes known to cause antibiotic resistance. We show that enriching for N. gonorrhoeae DNA prior to sequencing can improve the detection of some AMR genes, and by testing several samples at the same time we can reduce the costs associated with this method.
Data summary The sequence data generated in this study are deposited in the European Nucleotide Archive (ENA, https://www.ebi.ac.uk/ena/browser/) and are publicly available under study code PRJEB64347. The authors confirm all supporting data, code and protocols are provided within the article or through supplementary data files.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Centers for Disease Control and Prevention, USA. This study was also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), UK. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or Department of Health. DWE is a Robertson Foundation Big Data Institute Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed by an NHS research ethics committee (East Midlands - Leicester Central Research Ethics Committee, reference 19/EM/0029) and ethical approval was given.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Repositories European Nucleotide Archive study code PRJEB64347.
Data Availability
The sequence data generated in this study are deposited in the European Nucleotide Archive and are publicly available under study code PRJEB64347.
